Answers are grounded in this paper and cite their sources.
We conducted a laboratory evaluation of the ability of commercial antigen-capture assays, the Rapid Analyte Measurement Platform (RAMP) and the VecTest wicking assay, as well as Real Time reverse transcriptase polymerase chain reaction (RT-PCR, Taqman) and Vero cell plaque assay to detect West Nile virus (WNV) in large mosquito pools. Real-Time PCR (Taqman) was the most sensitive, detecting WNV ribonucleic acid (RNA) in 100% of samples containing a single infected mosquito in pool sizes of up to 500 mosquitoes. Mosquito body tissues minimally impacted the ability of Real Time RT-PCR to detect WNV in a pool size of 500, reducing sensitivity by 0.6 log10 plaque-forming units (PFU)/ml. Vero cell plaque assay detected live virus from a single infected mosquito in 100% of pools containing up to 200 mosquitoes, but was unreliable at larger pool sizes. VecTest detected 100% of positive pools containing 50 mosquitoes with 5.8 log10 PFU/ml virus, 100 mosquitoes with 5.9 log10 PFU/ml, and 200 mosquitoes with 5.2 log10 PFU/ ml. The RAMP assay detected 100% of positive pools containing 50 mosquitoes with 3.3 log10 PFU/ml virus, 100 mosquitoes with 3.7 log10 PFU/ml, and 200 mosquitoes with 4.0 log10 PFU/ml. Results indicate that WNV can be reliably detected by all 4 assays in pools of mosquitoes exceeding 50 specimens, though there is some loss of sensitivity with very large pool sizes.
No takes yet. Share an insight, caveat, or question.
SUTHERLAND et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: